PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing
Posted Date:
Sep 16, 2024
Due Date:
Sep 28, 2024
Awarded Date:
Sep 13, 2024
| SetAside Type | ||
| Solicitation ID | Solicitation Title | Solicitation Office |
| 75N91024D00008 | PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing | |
| Synopsis | ||
|
PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for cGMP Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing .... Read More
|
||
| Office Location | Agency Name | Solicitation Base Posting Type |
| NATIONAL INSTITUTES OF HEALTH | AWARD Notice | |
